ADC Therapeutics SA (ADCT) Misses Q3 EPS by 1c; Reports $530.2M of Cash and Cash Equivalents

ADC Therapeutics SA (NYSE: ADCT) reported Q3 EPS of ($0.93), $0.01 worse than the analyst estimate of ($0.92). Revenue for the quarter came in at $13.1 million versus the consensus estimate of $7.39 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Vivos Therapeutics posts 35% revenue gain but widens net loss